Preventing leukemia by preventing rogue blood cells from taking over

Study suggests a way to curb clonal hematopoiesis — and prevent leukemia — by targeting rogue clones’ anti-inflammatory defenses.

As we age, many of us acquire mutations that cause some of our blood stem cells to multiply faster than others, forming their own distinct populations or “clones.” This is known as clonal hematopoiesis. In some cases, a single clone originating from a single genetically altered or mutated stem cell can expand to make up as many as 30 percent of a person’s blood cells.

If such a “rogue” clone acquires more mutations, it can lead to myelodysplasia, a rare blood disease, and in turn to leukemia. The lab of Leonard Zon, MD, director of the Stem Cell Research program at Boston Children’s Hospital, wondered if these rogue populations could be nipped in the bud, preventing a potentially fatal leukemia from ever starting.

If so, it could help both adults who develop clonal hematopoiesis as they age and children with a variety of blood disorders like Shwachman-Diamond syndrome, GATA2 deficiency, or RUNX1 familial platelet disorder, in which clonal hematopoiesis can develop in childhood.

“These children have a germline mutation that puts them at risk for developing leukemia earlier in life,” explains Serine Avagyan, MD, PhD, a pediatric oncologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and a fellow in the Zon lab. “They can develop clonal hematopoiesis in adolescence and sometimes at a younger age. We think these predisposition syndromes fast-forward the process of clonal hematopoiesis, resulting in an early-onset leukemia.”

Tracking blood stem cells with colored ‘barcodes’

It’s been assumed that certain stem cell populations become dominant — and ultimately cancerous — because they gain some kind of edge through a genetic mutation. Or, as Charles Darwin might have put it, they become more “fit.” But how?

“If you could understand how clones of blood stem cells become cancerous, you could specifically target the offending clone that’s causing the problem,” says Zon.

That’s where Zon’s team, led by Avagyan and Jonathan Henninger, PhD, now at the Whitehead Institute for Biomedical Research, turned to zebrafish. A favorite tool of the Zon Lab, zebrafish are easy to breed and their embryos are translucent. That see-through quality enables scientists to watch developing blood cells in real time and observe the effects of different genetic mutations.

Once an errant gene is found, multiple drugs can be tested at a mass scale, simply by adding them to the fishes’ water. To date, Zon credits zebrafish for revealing four different drugs that have gone into clinical trials for melanoma, Diamond-Blackfan anemia, and adenoid cystic carcinoma, as well as a drug to enhance cord blood transplants.

As reported November 5 in the journal Science, Zon’s team used a zebrafish model called Zebrabow in which different cell colors serve as “barcodes” of their identity. In normal zebrafish, blood stem cells are of multiple colors, indicating their diversity. Using CRISPR, the team introduced different mutations found in human clonal hematopoiesis into the embryonic fish. They then watched to see whether one color of stem cell became dominant as a result — indicating that a rogue population of blood cells had taken hold.

“Serine was able to create mosaic mutations, such that some of the blood stem cells had the mutation and others didn’t,” says Zon. “We could then ‘compete’ the cells in the fish’s body to see which mutations caused a certain line of cells to take over.”

Suppressing rogue stem cells to curb leukemia

Indeed, certain mutations, such as in the gene asxl1, did lead to one blood stem cell population — and a single color of cell — becoming dominant in the zebrafish. The researchers then went further, examining what genes different kinds of blood cells were turning on as a result.

Mature white blood cells with mutations that cause clonal hematopoiesis turned on a host of inflammatory genes. In contrast, mutated blood stem cells turned on anti-inflammatory genes and were making anti-inflammatory molecules — protecting themselves against inflammation. When the team knocked out one of these protective genes, nr4a1, that mutant clone lost its fitness advantage and became less dominant.

“There has been a lot of evidence that the bone marrow is really inflamed in patients with clonal hematopoiesis,” says Zon. “But this is one of the first studies to demonstrate that there are pathways in stem cells that make them resistant to the inflammation.”

Zon and Avagyan believe that taking out that resistance factor could lead to strategies for halting clonal hematopoiesis and stopping leukemia at its earliest stage.

To that end, Zon and colleagues plan to search for a small-molecule drug that would target nr4a1 or related anti-inflammatory factors, a first step toward a clinical trial that would seek to reduce the risk of leukemia in people with clonal hematopoiesis and high-risk mutations. If they succeed, the drug would add to the arsenal of drugs the lab has discovered for patients with blood disorders and cancer — thanks to zebrafish.

The study was funded by the National Institutes of Health, Pedal for Pediatrics, Alex’s Lemonade Stand Foundation, and The Babich Family Foundation, and the Howard Hughes Medical Institute.

About Boston Children’s Hospital

Boston Children’s Hospital is ranked the #1 children’s hospital in the nation by U.S. News & World Report and is the primary pediatric teaching affiliate of Harvard Medical School. Home to the world’s largest research enterprise based at a pediatric medical center, its discoveries have benefited both children and adults since 1869. Today, 3,000 researchers and scientific staff, including 10 members of the National Academy of Sciences, 25 members of the National Academy of Medicine and 12 Howard Hughes Medical Investigators comprise Boston Children’s research community. Founded as a 20-bed hospital for children, Boston Children’s is now a 415-bed comprehensive center for pediatric and adolescent health care. For more, visit our Answers blog and follow us on social media @BostonChildrens, @BCH_Innovation, Facebook and YouTube.

Journal: Science
Article Title: Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis
Article Publication Date: 5-Nov-2021
COI Statement: Leonard Zon is a founder and stockholder of Fate Therapeutics, CAMP4Therapeutics, and Scholar Rock, outside the submitted work. All other authors declare that they have no competing interests.

Media Contact

Kristen Dattoli
Boston Children’s Hospital
kristen.dattoli@childrens.harvard.edu
Office: 617-820-8975, 617-919-3110

www.childrens.harvard.edu